Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 21Gastrointestinal 10Thoracic 5Breast 5Sarcoma 4Tumor-Agnostic 3Other solid neoplasm 3Other hematologic neoplasm 3Head & Neck 3Gynecologic 3Dermatologic 3CNS 3Plasma cell 2NET 1Myeloid 1Lymphoid 1Endocrine 1Classical hematology 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 10lutetium Lu 177 dotatate 7Magnetic Resonance Spectroscopy 7pasireotide 4Specimen Handling 3Positron Emission Tomography Computed Tomography 3Nivolumab 3Ga(III)-DOTATOC 3Fluorodeoxyglucose F18 3(177)Lu-DOTA-EB-TATE 3olaparib 2gallium Ga 68 dotatate 2amino-acid, glucose, and electrolyte solution 2Temozolomide 2Lutetium-177 2Ipilimumab 2FAPI-46 2veliparib 1vandetanib 1trifluridine tipiracil drug combination 1toripalimab 1tislelizumab 1talazoparib 1surufatinib 1romidepsin 1peposertib 1pembrolizumab 1pelcitoclax 1pegfilgrastim 1lanreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × cabozantinib × NET × Clear all
NCT05249114 2026-04-13

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Providence Health & Services

Phase 1 Active not recruiting
6 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡